Practical issues in the use of levilimab, a novel interleukin-6 receptor inhibitor, in patients with rheumatoid arthritis

Download in PDF

Levilimab is a monoclonal antibody targeting interleukin-6 receptors and having a potent anti-inflammatory activity. Efficacy and safety of levilimab for treatment of rheumatoid arthritis were established in multicenter, double blind, placebo-controlled clinical trials AURORA and SOLAR. The authors present two patients with rheumatoid arthritis who were treated successfully with levilimab and discuss various issues of its use in clinical practice.

Key words

Levilimab, IL-6 receptor inhibitor, rheumatoid arthritis, treatment.